Universitätsklinikum Heidelberg

Die Arbeits- und Weiterbildungssituation junger Ärztinnen und Ärzte in Deutschland – eine zusammenfassende Analyse von Befragungsergebnissen aus sechs Fachrichtungen (2020) Joachim SC, Bitzinger D, Arnold H, Lermann J, Oechtering TH, Schott S, Schulte K, Raspe M Journal article Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients (2020) Amaral T, Kiecker F, Schaefer S, Stege H, Kaehler K, Terheyden P, Gesierich A, et al. Journal article Malformationen des Zentralnervensystems - Seltene Ursachen eines organischen Wachstumshormonmangels bei Kindern (2020) Dörr HG, Bettendorf M, Binder G, Hauffa B, Mohnike K, Mueller HL, Reinehr T, et al. Journal article Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies (2020) Schneeweiss A, Hartkopf AD, Mueller V, Woeckel A, Lux MP, Janni W, Ettl J, et al. Journal article, Review article Bioactive glass (Bg) icie16 shows promising osteogenic properties compared to crystallized 45s5-bg (2020) Westhauser F, Hohenbild F, Arango Ospina M, Schmitz SI, Wilkesmann S, Hupa L, Moghaddam A, Boccaccini AR Journal article Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany (2020) Heratizadeh A, Haufe E, Stoelzl D, Abraham S, Heinrich L, Kleinheinz A, Wollenberg A, et al. Journal article A Randomized Phase II Study of Nivolumab Plus Ipilimumab Versus Standard of Care in Previously Untreated and Advanced Non-Clear Cell Renal Cell Carcinoma (Suniforecast) (2020) Ahrens M, Escudier B, Boleti E, Grimm MO, Goupir MG, Barthelemy P, Gravis G, et al. Conference contribution Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab (CD-Bev) vs. Carboplatin/Gemcitabine/Bevacizumab (CG-BEV) in Patients with Recurrent Ovarian Cancer: a Prospective Randomized Phase iii Engot/GCiG-Intergroup Study (Ago Study Group, Ago-AUSTRiA, ANZGOG,GiNECO, SGCTG) (2020) Hanker L, Harter P, Sehoul L, Rau J, Canzler U, Schmalfeldt B, Thiel F, et al. Conference contribution Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution Serio - Side Effect Registry in Immuno-Oncology (2020) Koutzamanidis R, Mentzer D, Knauss S, Broeckelmann PJ, Hassel JC, Ugurel-Becker S, Pavel ME, et al. Conference contribution